Linguamatics Extends License to Text Mining Platform to AstraZeneca

Cambridge, UK (OBBeC) - Linguamatics, a provider of enterprise text mining for the life science and other markets, has announced that AstraZeneca, a customer of Linguamatics since 2003, has extended its license to the I2E semantic knowledge-discovery platform with a further multi-year deal. I2E provides flexible and scalable enterprise text mining within AstraZeneca’s knowledge engineering strategy, and supports decision making at many points in the drug discovery process, including target selection, biomarker discovery and safety/tox. Financial details of the agreement were not disclosed.



“AstraZeneca’s researchers need efficient access to relevant biomedical knowledge,” commented Roger Hale, COO and Co-founder of Linguamatics. “I2E uses agile NLP-based text mining technology to provide high quality insights from literature sources in real-time, supporting key decisions with the right information at the right time.” 

“The early prediction of candidate drug efficacy and safety is paramount in any successful drug discovery campaign,” said Ian Dix, Knowledge Engineering Capability Lead, Discovery Information, AstraZeneca. “I2E is being used for knowledge discovery to support better-informed scientific decision-making, impacting discovery performance and competitiveness.”